• GreenBone Ortho

  Participated · Equity · Sep 2015

  GreenBone Ortho SpA develops bio-inspired, off-the-shelf 3D bone grafts built from natural wood-derived scaffolds incorporating resorbable nano-crystalline hydroxyapatite, beta-tricalcium phosphate, magnesium and strontium. The cell-free, growth-factor-free scaffold is highly porous and has demonstrated the ability to drive de novo bone mineralisation at ectopic sites; two international clinical studies are ongoing and a CE-mark was granted in December 2019 for a portfolio addressing large segmental bone defects. The company plans to use the new funding to expand clinical indications such as spinal and maxillofacial surgery, build a new production line, and support the market launch of the approved product. GreenBone has raised EUR22 million in equity since its 2015 founding in Faenza, Italy, including the EUR10 million Series B just closed. The technology aims to offer an alternative to traditional bone grafts and transplants by mimicking natural bone chemistry and 3D architecture to improve outcomes for large bone replacements. Management and the new board include experienced investors and industry executives who will support clinical and commercial roll-out. GreenBone, founded in 2014 and based in Faenza, Italy, develops a patented wood-derived, biomimetic and resorbable scaffold for bone regeneration targeting long-bone non-unions, spinal damage, trauma and cancer-induced bone loss. Its core product is a bio-inspired bone implant designed to regenerate functional bone and reduce healthcare and social costs for patients with severe skeletal damage. The company has completed pre-clinical studies in cooperation with Assaf-Harofeh Hospital and the Rizzoli Orthopedic Institute and holds granted patents in the USA, EU, China and other countries with a PCT application pending. GreenBone intends to complete clinical development in load-bearing long-bone defects and pursue CE marking, while also conducting pre-clinical development for additional skeletal applications. Financially, the company closed a €3 million seed round in 2015 and has secured a €2 million investment from Helsinn Investment Fund as part of a wider fundraising. Management is described as experienced and having advanced multiple orthopedic products from bench to market. GreenBone develops a wood-derived bone implant technology designed to generate biomimetic, reabsorbable load-bearing implants suitable for addressing non-union fractures. The implant concept was conceived and developed by a research group at ISTEC-CNR (Andrea Ruffini, Simone Sprio and Anna Tampieri). The company plans to continue platform development, run clinical studies on patients with bone damages and obtain the CE mark. GreenBone is an Innovative Startup under Italian law. In its first venture capital funding the company raised €3m to support those development and regulatory efforts. The company was founded in 2014 and is based in Faenza, Italy.

• Fazland

  Participated · Series A · Sep 2015

  Fazland operates an online and mobile marketplace that lets users request services and receive personalized quotes from professionals across home, business, personal and event categories. Users can compare proposals and close deals by phone through the platform. The company reports over 1,000 daily requests, more than 500,000 monthly views and had over €1m turnover in 2016. Fazland was co-founded in 2012 by Vittorio Guarini, Alessandro Iotti, Giovanni Azzali and Federico Panini and is based in Reggio Emilia, Italy. It intends to use new capital to continue expanding its operations. To date the company has raised more than €6m in funding. Fazland operates an online marketplace that connects service providers to people in need, allowing providers to describe skills and users to compare proposals by price, certifications and reviews. The platform is likened to Thumbtack in the USA and has helped over 20,000 home services providers expand their business and acquire new clients. Fazland is already present in Romania and Germany and plans to use new funding to grow further in Italy and across Europe. The company intends to expand its category offerings beyond home services into personal care (photographers, personal trainers, etc.) and business services (accounting, translation, consultants). Founded in 2012, its leadership includes CEO Vittorio Guarini, COO Alessandro Iotti, CPO Giovanni Azzali and CTO Federico Panini. The company recently raised a €1M Series A to support these expansion plans.

• Angiodroid

  Participated · Equity · Jul 2015

  Angiodroid develops and commercializes an automatic CO2 dosing control system for angiographic imaging. Its CO2 injector is patented in Europe and the US and pending in China, and is commercialized in more than 55 countries. The system is designed to enable safer angiograms with fewer side effects while delivering imaging quality equal to standard contrast agents. Angiodroid has established commercial partnerships with MedTech companies including NGC Medical–Medtronic, Siemens Healthcare and Philips. Led by founder and CEO Sebastiano Zannoli, the company reported 2022 turnover of over €3M. The company is also developing Angiopulse, an IABP console for passive counterpulsation therapy, as part of its product roadmap. Angiodroid is a medical technology company based in San Lazzaro di Savena (Bologna), Italy, led by Founder and CEO Sebastiano Zannoli. It has developed a patented and CE‑marked exclusive automatic injection system for carbon dioxide angiography. The company cites core expertise in interventional cardiology, interventional radiology and vascular surgery. Angiodroid plans to use new funding to increase sales efforts and to introduce new products in its sector of focus. The article reports the company raised €1.5m in funding from strategic backers. A prior related round in October 2013 raised €900K. Angiodroid srl is a medical technology company headquartered in San Lazzaro di Savena (Bologna) with core expertise in hemodynamics, vascular surgery and interventional radiology. The company has developed a patented, CE-marked automatic injection system for carbon dioxide angiography accompanied by a disposable catheter kit. Founded by Sebastiano Zannoli (CEO) and Samuele Zannoli (software development manager), Angiodroid has partnered with hospitals such as San Raffaele (Milan), technology manufacturers and sales distributors. In October 2013 it raised €900K from business angels including investors associated with Italian Angels for Growth and Zernike MetaVentures (via the Ingenium Emilia Romagna fund). The company intends to use the funds to develop and commercialize new solutions in 2014 and to strengthen its sales force across Europe, India, Canada, the Middle East, China, Brazil and Africa.

• Condomani

  Participated · Equity · Apr 2014

  Condomani.it operates an online social network and condominium management platform that helps managers, house co-owners, professionals and providers handle condominium issues. The platform supports accounting, payments, budgets, works, intervention requests, mail, e-mail and SMS notices. It is used as a collaboration and administrative tool connecting stakeholders involved in building management. The company reports the platform is currently used to manage over 6,000 buildings nationwide. Condomani intends to use newly raised funds to continue to expand operations. The business was co-founded in 2013 by Antonio Bevacqua (CEO) and Federica Sesti Osseo and is also led by CTO Francesco Pipita.

• Flazio

  Led · Equity · Mar 2014

  Flazio is a DIY platform that allows users with no programming skills to build and manage websites via a web app. The web app enables users to add video, audio and e-commerce capabilities. It also automatically creates an accessible version for mobile devices. The company is led by founder and CEO Flavio and Elisa Fazio and is based in Catania, Italy. According to reports, Flazio raised €400k in funding. Backers include Beasy Lab and ZernikaMeta Ventures, which invested via Fondo Ingenium Catania.

No current team members are available.